1
|
Nurlybekova A, Kudaibergen A, Kazymbetova A, Amangeldi M, Baiseitova A, Ospanov M, Aisa HA, Ye Y, Ibrahim MA, Jenis J. Traditional Use, Phytochemical Profiles and Pharmacological Properties of Artemisia Genus from Central Asia. Molecules 2022; 27:molecules27165128. [PMID: 36014364 PMCID: PMC9415318 DOI: 10.3390/molecules27165128] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2022] [Revised: 08/05/2022] [Accepted: 08/05/2022] [Indexed: 12/04/2022] Open
Abstract
The flora of Kazakhstan is characterized by its wide variety of different types of medicinal plants, many of which can be used on an industrial scale. The Traditional Kazakh Medicine (TKM) was developed during centuries based on the six elements of ancient Kazakh theory, associating different fields such as pharmacology, anatomy, pathology, immunology and food nursing as well as disease prevention. The endemic Artemisia L. species are potential sources of unique and new natural products and new chemical structures, displaying diverse bioactivities and leading to the development of safe and effective phytomedicines against prevailing diseases in Kazakhstan and the Central Asia region. This review provides an overview of Artemisia species from Central Asia, particularly traditional uses in folk medicine and the recent numerous phytochemical and pharmacological studies. The review is done by the methods of literature searches in well-known scientific websites (Scifinder and Pubmed) and data collection in university libraries. Furthermore, our aim is to search for promising and potentially active Artemisia species candidates, encouraging us to analyze Protein Tyrosine Phosphatase 1B (PTP1B), α-glucosidase and bacterial neuraminidase (BNA) inhibition as well as the antioxidant potentials of Artemisia plant extracts, in which endemic species have not been explored for their secondary metabolites and biological activities so far. The main result of the study was that, for the first time, the species Artemisia scopiformis Ledeb. Artemisia albicerata Krasch., Artemisia transiliensis Poljakov, Artemisia schrenkiana Ledeb., Artemisia nitrosa Weber and Artemisia albida Willd. ex Ledeb. due to their special metabolites, showed a high potential for α-glucosidase, PTP1B and BNA inhibition, which is associated with diabetes, obesity and bacterial infections. In addition, we revealed that the methanol extracts of Artemisia were a potent source of polyphenolic compounds. The total polyphenolic contents of Artemisia extracts were correlated with antioxidant potential and varied according to plant origin, the solvent of extraction and the analytical method used. Consequently, oxidative stress caused by reactive oxygen species (ROS) may be managed by the dietary intake of current Artemisia species. The antioxidant potentials of the species A. schrenkiana, A. scopaeformis, A. transiliensis and Artemisia scoparia Waldst. & Kitam. were also promising. In conclusion, the examination of details between different Artemisia species in our research has shown that plant materials are good as an antioxidant and eznyme inhibitory functional natural source.
Collapse
Affiliation(s)
- Aliya Nurlybekova
- The Research Center for Medicinal Plants, Al-Farabi Kazakh National University, al-Farabi Ave. 71, Almaty 050040, Kazakhstan
- Research Institute for Natural Products & Technology, Almaty 050046, Kazakhstan
| | - Aidana Kudaibergen
- The Research Center for Medicinal Plants, Al-Farabi Kazakh National University, al-Farabi Ave. 71, Almaty 050040, Kazakhstan
- Research Institute for Natural Products & Technology, Almaty 050046, Kazakhstan
| | - Aizhan Kazymbetova
- The Research Center for Medicinal Plants, Al-Farabi Kazakh National University, al-Farabi Ave. 71, Almaty 050040, Kazakhstan
- University of Chinese Academy of Sciences, Beijing 100049, China
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
| | - Magzhan Amangeldi
- The Research Center for Medicinal Plants, Al-Farabi Kazakh National University, al-Farabi Ave. 71, Almaty 050040, Kazakhstan
- University of Chinese Academy of Sciences, Beijing 100049, China
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
| | - Aizhamal Baiseitova
- The Research Center for Medicinal Plants, Al-Farabi Kazakh National University, al-Farabi Ave. 71, Almaty 050040, Kazakhstan
- Research Institute for Natural Products & Technology, Almaty 050046, Kazakhstan
| | - Meirambek Ospanov
- The Research Center for Medicinal Plants, Al-Farabi Kazakh National University, al-Farabi Ave. 71, Almaty 050040, Kazakhstan
- National Center for Natural Products Research, School of Pharmacy, University of Mississippi, Oxford, MS 38677, USA
| | - Haji Akber Aisa
- Xinjiang Technical Institutes of Physics and Chemistry, Central Asian of Drug Discovery and Development, Chinese Academy of Sciences, Urumqi 830011, China
| | - Yang Ye
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
| | - Mohamed Ali Ibrahim
- National Center for Natural Products Research, School of Pharmacy, University of Mississippi, Oxford, MS 38677, USA
- Correspondence: (M.A.I.); (J.J.)
| | - Janar Jenis
- The Research Center for Medicinal Plants, Al-Farabi Kazakh National University, al-Farabi Ave. 71, Almaty 050040, Kazakhstan
- Research Institute for Natural Products & Technology, Almaty 050046, Kazakhstan
- University of Chinese Academy of Sciences, Beijing 100049, China
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
- Xinjiang Technical Institutes of Physics and Chemistry, Central Asian of Drug Discovery and Development, Chinese Academy of Sciences, Urumqi 830011, China
- Correspondence: (M.A.I.); (J.J.)
| |
Collapse
|
2
|
Large Scale Conversion of Trilobolide into the Payload of Mipsagargin: 8- O-(12-Aminododecanoyl)-8- O-Debutanoylthapsigargin. Biomolecules 2020; 10:biom10121640. [PMID: 33291419 PMCID: PMC7762042 DOI: 10.3390/biom10121640] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2020] [Revised: 11/26/2020] [Accepted: 12/03/2020] [Indexed: 12/11/2022] Open
Abstract
In spite of the impressing cytotoxicity of thapsigargin (Tg), this compound cannot be used as a chemotherapeutic drug because of general toxicity, causing unacceptable side effects. Instead, a prodrug targeted towards tumors, mipsagargin, was brought into clinical trials. What substantially reduces the clinical potential is the limited access to Tg and its derivatives and cost-inefficient syntheses with unacceptably low yields. Laser trilobum, which contains a structurally related sesquiterpene lactone, trilobolide (Tb), is successfully cultivated. Here, we report scalable isolation of Tb from L. trilobum and a transformation of Tb to 8-O-(12-aminododecanoyl)-8-O-debutanoylthapsigargin in seven steps. The use of cultivated L. trilobum offers an unlimited source of the active principle in mipsagargin.
Collapse
|